Susquehanna International Group, LLP Atai Life Sciences N.V. Call Options Transaction History

Susquehanna International Group, LLP

  • $560 Billion
  • Q3 2024

Call Options

12 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$1.16 - $1.64 $22,620 - $31,979
19,500 New
19,500 $22,000
Q1 2024

May 07, 2024
BUY
$1.5 - $2.19 $172,350 - $251,631
114,900 Added 309.7%
152,000 $299,000
Q4 2023

Feb 14, 2024
SELL
$1.04 - $1.55 $31,304 - $46,655
-30,100 Reduced 44.79%
37,100 $52,000
Q3 2023

Nov 14, 2023
SELL
$1.27 - $2.28 $162,052 - $290,928
-127,600 Reduced 65.5%
67,200 $86,000
Q2 2023

Aug 11, 2023
BUY
$1.44 - $2.19 $108,864 - $165,564
75,600 Added 63.42%
194,800 $335,000
Q1 2023

May 16, 2023
BUY
$1.17 - $2.7 $46,449 - $107,190
39,700 Added 49.94%
119,200 $215,000
Q4 2022

Feb 14, 2023
SELL
$2.38 - $3.55 $256,802 - $383,045
-107,900 Reduced 57.58%
79,500 $211,000
Q3 2022

Nov 14, 2022
SELL
$3.14 - $4.87 $3,140 - $4,870
-1,000 Reduced 0.53%
187,400 $620,000
Q2 2022

Aug 15, 2022
SELL
$3.03 - $5.32 $32,723 - $57,456
-10,800 Reduced 5.42%
188,400 $686,000
Q1 2022

May 16, 2022
BUY
$4.66 - $7.66 $627,236 - $1.03 Million
134,600 Added 208.36%
199,200 $1.01 Million
Q4 2021

Feb 14, 2022
BUY
$6.82 - $17.8 $319,176 - $833,040
46,800 Added 262.92%
64,600 $493,000
Q3 2021

Nov 15, 2021
BUY
$13.62 - $19.48 $242,436 - $346,744
17,800 New
17,800 $263,000

Others Institutions Holding ATAI

# of Institutions
87
Shares Held
12.4M
Call Options Held
77.8K
Put Options Held
50.3K
View Full List

About ATAI Life Sciences N.V.

ATAI Quotes by TradingView
  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $245M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email